Ratings Moves: ING,...
Health Care: Drugs
Astex Pharmaceuticals Inc (ASTX: NASDAQ)
$5.36 0.24 | 4.69%
05/24/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 83.16M | 66.91M | 52.97M | 41.25M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 83.16M | 66.91M | 52.97M | 41.25M |
| Selling, General, and Administrative Expenses | 15.66M | 16.84M | 9.44M | 9.59M |
| Research & Development | 60.42M | 43.90M | 28.39M | 29.69M |
| Operating Income before D & A (EBITDA) | 7.08M | 6.18M | 15.14M | 1.98M |
| Depreciation & Amortization | 9.53M | 5.90M | 1.28M | 1.33M |
| Interest Income | 188.00K | 226.00K | 182.00K | 686.00K |
| Other Income - Net | 2.08M | 316.00K | 994.00K | 1.19M |
| Special Income / Charges | -6.13M | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -6.31M | 817.00K | 15.03M | 2.52M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -6.31M | 817.00K | 15.03M | 2.52M |
| Income Taxes | -13.03M | -3.29M | 39.00K | -886.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | 8.25M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 8.25M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 8.25M | 5.54M | 16.27M | 4.74M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
14.37M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 8.25M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | 0.09 | 0.07 | 0.27 | 0.08 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 0.09 | 0.07 | 0.27 | 0.08 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 0.09 | 0.07 | 0.27 | 0.08 |
| Basic Normalized Net Income/Share | 0.16 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | 0.08 | 0.07 | 0.27 | 0.08 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 0.08 | 0.07 | 0.27 | 0.08 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 0.08 | 0.07 | 0.27 | 0.08 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.14 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ASTX
- Portfolio NameUser Type
- UserMy SP portfolio
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserGopher Gold
- ContributorStocks Under-$10 Moving Hig...
Latest ASTX Headlines from TheStreet
- Astex Pharmaceuticals To Present At UBS Global Healthcare Conference 05.14.13 | 06:05 am
- Short Interest Moves 16% Higher For ASTX 05.10.13 | 03:05 pm
- Astex Pharmaceuticals Inc Stock Downgraded (ASTX) 05.01.13 | 05:05 am
- Astex Pharmaceuticals Reports 2013 First Quarter Financial Results 04.29.13 | 04:04 pm
- Astex Pharmaceuticals To Present At Needham Healthcare Conference 04.23.13 | 06:04 am
- Astex Pharmaceuticals To Announce 2013 First Quarter Financial Results On April 29th 04.22.13 | 06:04 am
- Astex Pharmaceuticals Provides SGI-110 Update 04.10.13 | 06:04 am
- Investing 'Systems' Take the Guesswork Out of Making Money 04.04.13 | 06:04 am
- Astex Pharmaceuticals Pipeline Data Presentations At AACR 04.03.13 | 06:04 am
- Astex Pharmaceuticals To Present At ROTH Conference 03.12.13 | 06:03 am
Press Releases for ASTX
- Astex Pharmaceuticals To Present At AACR Annual Meeting - Business Wire 03.29.12 | 06:03 am
- Astex Pharmaceuticals Announces March 27th Analyst And Investor Day Agenda - Business Wire 03.21.12 | 06:03 am
- Eisai Inc. Receives Complete Response Letter From The U.S. Food And Drug Administration For Dacogen® (decitabine) For Injection SNDA In Acute Myeloid Leukemia - Business Wire 03.06.12 | 09:03 pm
- Astex Pharmaceuticals Reports 2011 Fourth Quarter And Year-End Financial Results - Business Wire 03.05.12 | 04:03 pm
- Astex Pharmaceuticals To Announce 2011 Fourth Quarter And Year-End Financial Results On March 5, 2012 - Business Wire 02.28.12 | 06:02 am
- Astex Pharmaceuticals To Host Annual Analyst And Investor Day On March 27, 2012 - Business Wire 02.16.12 | 06:02 am
- FDA’s Oncologic Drugs Advisory Committee (ODAC) Votes To Not Support Benefit/Risk Profile Of DACOGEN® (decitabine) In Acute Myeloid Leukemia - Business Wire 02.09.12 | 01:02 pm
- Astex Pharmaceuticals Announces Presentations At Upcoming Conferences - Business Wire 02.06.12 | 06:02 am
- Astex Announces Early Transfer Of Epigenetics Project To GSK - Business Wire 01.16.12 | 06:01 am
- Astex Pharmaceuticals To Present At Biotech Showcase On January 9th - Business Wire 01.03.12 | 06:01 am
Partner Headlines for ASTX
- Astex Pharmaceuticals: Heading For New Highs On Strong Pipeline Momentum - Seeking Alpha 01.10.13 | 09:01 am
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- Astex's Linear Rise Versus Peregrine's And Cell Therapeutics' Sudden Pop - Seeking Alpha 09.10.12 | 09:09 am
- One Stock To Buy, Two Avoids, And A Swing Trade From Last Week's Big Biotech News Movers - Seeking Alpha 07.21.12 | 06:07 am
- 3 Rising Biotech Stars All Under $2/Share - Seeking Alpha 06.18.12 | 09:06 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Cyclacel: An Intriguing Long Shot - Seeking Alpha 03.20.12 | 08:03 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
